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hamsters, while inhibiting production of betaine,
carnitine, and choline metabolites
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Abstract
Background: Previously, we reported that ProAlgaZyme (PAZ) and its biologically active fraction improved plasma
lipids in hypercholesterolemic hamsters, by significantly increasing the high density lipoprotein cholesterol (HDL-C)
while reducing non-HDL cholesterol and the ratio of total cholesterol/HDL-C. Moreover, hepatic mRNA expression
of genes involved in HDL/reverse cholesterol transport were significantly increased, while cholesteryl ester transfer
protein (CETP) expression was partially inhibited. In the current study, we investigated the therapeutic efficacy of
the biologically active fraction of PAZ (BaP) on the plasma lipid and plasma metabolomic profiles in diet induced
hypercholesterolemic hamsters.
Methods: Fifty male Golden Syrian hamsters were fed a high fat diet for 4 weeks prior to randomization into
6 groups, based on the number of days they received subsequent treatment. Thus animals in T0, T3, T7, T10,
T14, and T21 groups received BaP for 0, 3, 7, 10, 14, and 21 days, respectively, as their drinking fluid. Plasma lipids
were assayed enzymatically, while real-time reverse transcriptase polymerase chain reaction (RT-PCR) provided the
transcription levels of the Apolipoprotein (Apo) A1 gene. The plasma metabolomic profile was determined using 1H
nuclear magnetic resonance (NMR) spectroscopy in conjunction with multivariate analysis.
Results: Plasma HDL-C was significantly increased in T3 (P < 0.05) and T21 (P < 0.001), while non-HDL cholesterol
was significantly reduced in T3, T7, T10 (P < 0.001) and T14, T21 (P < 0.01). Moreover, the ratio of total cholesterol/
HDL-C was significantly lower in all BaP treated groups (P < 0.001) as compared with T0. Quantitative RT-PCR
showed an increase in Apo A1 expression in T10 (3-fold) and T21 (6-fold) groups. NMR data followed by
multivariate analysis showed a clear separation between T0 and T21 groups, indicating a difference in their
metabolomic profiles. Plasma concentrations of metabolites associated with a risk for atherosclerosis and
cardiovascular disease, including choline, phosphocholine, glycerol-phosphocholine, betaine and carnitine
metabolites were significantly lower in the T21 group.
Conclusion: Treatment with BaP significantly improved the plasma lipid profile by increasing HDL-C and lowering
non-HDL cholesterol. In addition, BaP potentially improved the plasma metabolomic profile by reducing the
concentration of key metabolites associated with risk for atherosclerosis and cardiovascular disease.
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ProAlgaZyme
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Introduction
The etiology of cardiovascular disease (CVD) has been
strongly linked with elevated levels of plasma low den-
sity lipoprotein cholesterol (LDL-C), accompanied by
reduced high density lipoprotein cholesterol (HDL-C)
concentrations [1]. Despite considerable advancements
in therapeutics to improve the plasma lipoprotein pro-
file, from statin drugs to dietary modifications, it is hard
to achieve a decline in cardiac events in practice, due to
the difficulties associated with determining optimal tar-
gets for such interventions. More recently, the interest
in functional foods (including some seaweed extracts,
freshwater and marine algal products), has drawn the
attention of the scientific community, due to their ability
to decrease plasma cholesterol and induce genetic modi-
fications with respect to lipoprotein metabolism [2-5].
ProAlgaZyme (PAZ) is the fermentation product of dif-
ferent freshwater organisms, mainly green and red algae,
and consists of a mixture of approximately 90% salts and
10% organic components [6]. The therapeutic effect of
PAZ on body weight, body mass index, fasting blood
glucose, blood lipids, and markers of inflammation was
first investigated by Oben et al. in patients with meta-
bolic syndrome [6]. These investigators concluded that
PAZ could be used as a dietary agent for prevention of
CVD, as the results showed a positive effect on various
parameters analyzed [6]. To better understand the effect
of PAZ on lipid metabolism, and to elucidate the me-
chanism by which the levels of HDL-C were increased,
we previously reported a study that analyzed different
subfractions of PAZ for their potential preventative
effect on lipids, when administered simultaneously to
animals on a high fat diet. Hepatic mRNA expression
was also analyzed to determine the effect of PAZ on
genes involved in HDL/reverse cholesterol transport in
diet induced hypercholesterolemic hamsters [7]. The goal
of the current study was to determine if the plasma lipid
profile in established hypercholesterolemic animals could
be improved by therapeutic intervention with the biologi-
cally (BaP) active fraction documented in the previous
study. Secondly, the current study aimed to determine the
time course required for the effect on lipid parameters.
However, as observed in recent reports, the lipid
profile does not provide a complete picture of disease
progression. Analysis of a multifactorial disease, such as
atherosclerosis and other forms of CVD, using a limited
number of biomarkers can lead to inaccurate diagnosis
and treatment regimes, weakening the advancement of
new therapies. In contrary, the omics-based approaches
(metabolomics, in particular) have allowed scientists to
characterize, at the molecular level, complex biological
systems and their changes in pathological processes
[8,9], providing an excellent tool for examining pheno-
types using descriptors for hundreds of metabolites.
Metabolomics analysis aims to detect changes in the
relative concentrations of endogenous small molecules
that characterize the changes in metabolism, thus help-
ing to reveal the metabolic state of biological systems
[10]. The metabolomic strategy has been successfully
used to investigate multiple distinct biological processes
including toxicological effects [11,12], disease processes
[13], and nutritional interventions [14,15]. Recently, nu-
tritional metabolomics has provided important insights
into understanding metabolic responses related to diet-
induced hypercholesterolemia and atherosclerosis [10,16].
Therefore, in addition to studying the effect of BaP on
the lipid profile, we used 1H nuclear magnetic resonance
(NMR) spectroscopy, a powerful tool for simultaneous
analysis of several hundreds or thousands of metabolites
in biological fluids such as urine or plasma [17], to get a
deeper insight into the metabolomic shift over time.
Thus, lipid profiles were correlated with the changes in
plasma metabolomic profiles. Data were analyzed using
multivariate analysis SIMCA P + software and targeted
profiling was applied to indentify and quantify the me-
tabolites that were different between the treatment and
control groups. Here we report the changes in the lipid
profile as compared and correlated with perturbations
in the plasma metabolomic profile due to dietary intake
of BaP.
Materials and methods
Animals and diets
Fifty 8-week-old male Golden Syrian hamsters (Mesocri-
cetus auratus), LVG strain (Charles River Laboratories,
Wilmington, MA), each weighing approximately 80 g, were
randomized into six groups: T0 (n = 10) and T3, T7, T10,
T14, and T21 (n = 8 per group). Upon arrival, they were
acclimatized and given water and laboratory rodent diet
5001 (Lab Diet, Richmond, IN) ad libitum for one week
prior to the initiation of the experimental study. For the
subsequent four weeks, hamsters were fed a high fat diet
containing 30% calories from fat (Dyets Inc., Bethlehem,
PA, Table 1). Distilled water was provided as their drinking
fluid. The composition of the high fat diet was shown to
induce a hypercholesterolemic state in the hamsters in our
previous study [7]. After four weeks, the hypercholestero-
lemic hamsters were provided with a 20% (v/v) solution of
BaP, as their drinking fluid [7]. The process of fractionation
of the PAZ has been detailed previously [7]. BaP was ad-
ministrated for 0 days (T0 group), 3 days (T3 group), 7 days
(T7 group), 10 days (T10 group), 14 days (T14 group), and
21 days (T21 group), respectively. Body weight as well as
food and fluid intake were recorded weekly. Animals were
housed individually in a temperature-controlled room
(25°C) maintained on a 12-h light/dark cycle. The study
protocol was approved by the Institutional Animal and
Care Use Committee at Wayne State University, Detroit.
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Plasma and tissue collection
Each group of hamsters was sacrificed at different time
points, based on the number of days of treatment with
BaP. Hamsters were fasted for 8 hours and anesthetized
under CO2/O2 (50:50) gas (Metro Welding, Detroit, MI)
prior to sacrifice. Blood was collected on ice by cardiac
puncture with syringes previously rinsed with potassium
EDTA solution (15% wt/v) and plasma was immediately
separated after centrifugation at 1000 × g for 15 minutes
at 4°C. Liver tissues were collected and immediately
flash frozen in liquid nitrogen for further analyses.
Plasma lipid analysis
Plasma triglycerides (TG) and total cholesterol (TC)
concentrations were determined enzymatically, while
HDL-C was measured in the supernatant following pre-
cipitation with the Mg 2+/dextran sulfate according to
the manufacturer’s protocol (Pointe Scientific, Canton,
MI), as detailed previously [7]. The concentration of
non-HDL cholesterol was calculated as the difference
between the measured TC and HDL-C, and includes the
sum of very low density lipoprotein, intermediate density
lipoprotein, and LDL-C.
Real-time reverse transcription polymerase chain reaction
(RT-PCR)
Total RNA from the liver was extracted using miRNeasy
Mini Kit (Qiagen, Valencia, CA) and reverse transcrip-
tion of RNA into cDNA was performed using the High
Capacity mRNA to cDNA Master Mix kit (Applied
Biosystems, Carlsbad, CA) as per the manufacturer’s
protocol. Total RNA was obtained by adding 40 μL
RNAase-free H2O followed by centrifugation at 1000 × g
for 1 minute. mRNA was further subjected to reverse
transcription using the High-Capacity RNA to cDNA
Master Mix kit. The reaction was carried in a total of
20 μL mixture (4 μL of Complete Master Mix, 8 μL of
total RNA, and 8 μL of nuclease-free H2O) in a Master
cycler (Eppendorf, Hauppauge, NY). The program was
set for 5 minutes at 25°C, 30 minutes at 42°C, 5 minutes
at 85°C, and 1 hour at 4°C. A 2 μL sample of the
obtained cDNA was used for each real-time RT-PCR
reaction using SYBR Green Master Mix (Applied
Biosystems) and an MX3005P instrument (Strategene,
Santa Clara, CA) to determine the relative transcription
levels of Apo A1(F: 5′-ACC-GTT-CAG-GAT-GAA-
AAC-TGT-AG-3′, R: 5′-GTG-ACT-CAG-GAG-TTC-
TGG-GAT-AAC-3′) [18]. The cycle conditions were
10 min at 95°C followed by 40 cycles of incubation at
95°C for 15 seconds, then 60°C for 1 minute. No accu-
mulations of nonspecific products or primer dimers were
observed using nontemplate control wells, as a result of
prior optimization with the concentration used. The data
were analyzed according to the comparative threshold
cycle (Ct) method and normalized by glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) expression in each
sample. Levels of mRNA expression were reported as fold
differences compared with hamsters fed the high fat diet
and water.
Plasma metabolomic analysis using 1H NMR
Plasma samples were diluted with deuterium oxide
(D2O) in a 4:1 ratio, and a reference buffer solution
(NMR solvent) containing 5 mmol/L disodium-2,2-di-
methyl 2-silapentane-5-sulphonate and 10 mmol/L imid-
azole in D2O (Sigma-Aldrish, Mississauga, ON) was
added in a 9:1 ratio (9 parts of diluted plasma sample : 1
part NMR solvent). After preparation, samples were trans-
ferred to 5 mm NMR tubes (Sigma-Aldrich, St. Louis,
MO) and 1H NMR spectra were acquired on a 600 MHz
Agilent spectrometer, operating at 599.773 MHz fre-
quency and a temperature of 300 K [10,19,20]. One-
dimensional NMR spectra were acquired using the
Carr-Purcell-Meiboom-Gill (CPMG) spin-echo sequen-
ce with presaturation, to attenuate broad signals from
proteins and lipoproteins. Application of the CPMG
pulse sequence resulted in spectra with signals from the
small molecular weight metabolites only, due to their
longer transverse relaxation time. These spectra were
measured using a spin-echo loop time of 0.16 s and a
recycling time of 14 s. A total of 64 scans were collected
using a spectral width of 10 ppm and an acquisition time
of 4 s. The NMR data were processed using ACD/Spec
Manager 7.00 software (Advanced Chemistry Development
Table 1 Composition of the experimental custom purified
diet with coconut oil and soybean oil
Ingredient kcal./gm grams/kg
Casein 3.58 110
Lactalbumin 3.9 110
L-Arginine 4 2.5
L-Tryptophan 4 0.3
Cornstarch 3.6 370.2
Dyetrose 3.8 175
Coconut Oil 9 138.6
Soybean Oil 9 1.4
TBHQ 0 0.028
Cellulose 0 44
Cholesterol 0 1
Mineral Mix #260001* 0 35
Vitamin Mix #360001** 3.84 10
Choline Bitartrate 0 2
Abbreviation: TBHQ Tertiary Butylhydroquinone.
* Hamster Mineral mix prepared by Dyets, Inc.
** Hamster Vitamin Mix prepared by Dyets, Inc.
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Inc., Toronto, Canada) and free induction decay files were
obtained. The acquired NMR spectra were processed by
editing, auto-phasing, and auto-baseline correction.
Intelligent binning was used to divide the edited spectra
into 1000 bins. The spectra were digitized to a table of
common integrals and exported as a non-negative value
text file for multivariate data analysis.
Multivariate data analysis
Data were statistically analyzed by principal component
analysis (PCA), partial least square (PLS) and PLS-
discriminant analysis (PLS-DA), using SIMCA-P + 13.0
software (Umetrics, Umea, Sweden). PCA is an unsuper-
vised multivariate projection method designed to extract
and display the systemic variation in the data matrix X
as a score plot [21]. The corresponding loading plot pro-
vides information about the part of the spectrum that is
responsible for the similarities and/or dissimilarities in
the data set as observed in the score plot. Moreover, the
orthogonal projections to latent structures (OPLS) aids
in the process of identifying statistically significant and
potentially biochemically significant metabolites based
on contribution to the model and their reliability. PLS is
a regression extension of PCA, which is used to connect
the information in two blocks of variables, X and Y, to
each other [19]. In PLS-DA the data set is distributed
into classes and its objective is to find a model that
separates the classes of observation on the basis of their
X-variables, while using a hypothetical Y-variable. Both
PLS and PLS-DA methods of analysis are supervised,
which implies that some information about the data set
is provided to the software prior to analysis [21]. PLS
was used to correlate the results from the 1H spectra
with other measured factors (TG, TC, HDL-C, TC/
HDL-C, non-HDL cholesterol), keeping these factors
as Y parameters. All data were Pareto-scaled prior to
analysis.
Each point on the score plots corresponds to an indi-
vidual animal, to expose specific grouping and the rela-
tionship between the samples. Each dot on the loading
plot represents a single NMR spectral area or bin, illus-
trating the significance of each metabolite for the vari-
ation described [22].
Identification and quantification of the metabolites in
spectra was accomplished using Chenomx NMR Suite
7.6 software (Chenomx, Alberta, Canada) [23], focusing
on the peaks of the spectra that differentiate the
groups. Chenomx software uses targeted profiling to
reduce analysis time, combining advanced analysis tools
with a compound library of approximately 300 meta-
bolites [24]. Once the changes in metabolite concen-
trations had been determined, the pathways affected by
the respective metabolites were identified using online
KEGG database.
Statistical analysis
All data evaluated the differences between the control
and treatment groups and were expressed as mean ±
standard error. The data were analyzed to determine the
effect of BaP relative to distilled water, while the animals
were fed a high fat diet. The significance of anthropo-
metric measurements and plasma lipid concentrations
were determined using one-way ANOVA tests (IBM
SPSS, Chicago, IL). All multivariate data analysis and
modeling were accomplished using PCA and PLS-DA.
PLS correlations were calculated to investigate the
relationships between plasma lipid profile and the meta-
bolomic profile of the hypercholesterolemic hamsters.
Identification and quantification of metabolites was
performed using Chenomx 7.6 software and the signifi-
cance between the groups was determined using two-
tailed Student t-test (Excel, Microsoft Office, Redmond,
WA). Significance was defined at P < 0.05.
Results
Metabolic effects of high-fat diet and BaP
supplementation
Animals were fed a high fat diet and water for the first
four weeks of the study, the end point for the T0 group.
After four weeks, groups T3, T7, T10, T14, and T21
received BaP as their drinking fluid for 3, 7, 10, 14, and
21 days, respectively, while continuing to consume the
high fat diet. Animals were sacrificed at different time
points, based on the number of days they were designed
to receive BaP treatment. The net body weight gain for
the first 4 weeks of the study, as well as the food effi-
ciency ratio (g gained/g feed) was statistically significant
in group T7 (P < 0.05, Table 2) when compared with
controls. The ratio of fluid/water intake and the ratio of
liver weight/body weight were not statistically different
when compared with the T0 group (Table 2). While on
treatment with BaP, all animals survived the duration of
the study and no abnormal characteristics related to the
physiology of the animals were noted.
Plasma lipid and lipoprotein profile
Plasma lipid profiles of the hypercholesterolemic ham-
sters were measured enzymatically to determine the
therapeutic effect of BaP when administrated as the
drinking fluid. Plasma TG and TC were not significantly
reduced in the treatment groups, as compared with the
control group (T0). However, the TC/HDL-C ratio was
significantly lower in all treatment groups when com-
pared with the control T0 group (P < 0.001, Table 3).
The concentration of HDL-C was significantly increased
in the T3 group (P < 0.05), as well as in the T21 group
(P < 0.001), when compared with the controls. Con-
sumption of BaP also significantly reduced the non-HDL
cholesterol in all groups, as compared with the control
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animals (P < 0.01). These results corroborate with our
previous findings that ingestion of PAZ and its biolo-
gically active fraction improves the plasma lipoprotein
profile by significantly increasing the HDL-C concentra-
tions, while decreasing the non-HDL cholesterol and
TC/HDL-C ratio in hypercholesterolemic hamsters, both
as preventative (previous study) and therapeutic (current
study) agent.
Hepatic mRNA gene expression of Apo A1
In order to determine the therapeutic potential of BaP at
the molecular level and to validate the significant
increase in HDL-C concentration, Apo A1 gene expres-
sion was evaluated. Also, the earliest time point at which
the genetic expression is altered was determined. Apo
A1 gene expression analysis showed that hamsters fed
BaP for 10 days (T10) had a moderate (3-fold) increase,
while hamsters fed BaP for 21 days exhibited an approxi-
mately 6-fold increase (Figure 1). This data correlates
with the increase in the plasma concentration of HDL-C
(Apo A1 being responsible for the production of nascent
HDL particles). Thus the BaP increased HDL-C, at least
in part, by increasing the production of nascent HDL
particles, both when given as a therapeutic or preventa-
tive agent [7]. However, unlike the previous study where
we saw a partial inhibition of CETP when PAZ was de-
livered as a preventative agent, no effects on CETP were
apparent using the therapeutic approach within the
timeframe of the current study (data not shown).
Multivariate data analysis and metabolites identification
on 1H NMR plasma
To further investigate the therapeutic effect of BaP on
the hypercholesterolemic hamsters, plasma samples
from controls (T0) and 21 days treatment group (T21)
were subjected to metabolomic analysis using 1H NMR
spectroscopy. PCA was performed on the NMR data to
get overall information on metabolomic effects, if any, in
hamsters due to BaP administration. The PCA score
plots showed a clear separation in clusters produced by
the T0 and T21 groups (Figure 2a), indicating differences
in their plasma metabolomics profiles. Since one of the
samples in the T21 group was outside the Hotelling’s
95% confidence interval (ellipse), it was considered to be
a strong outlier and removed from the PCA analysis.
The corresponding loading plot (Figure 2b) along with
the S Plot (Figure 2c) provided important information
on the contribution of each variable to the clustering
pattern in the score plots. Both of these loading plots
were used as a visual method to select and identify me-
tabolites of interest for further analysis. In addition, the
specific metabolites in the S-Plot reflected those strongly
correlating with the changes in the plasma HDL-C
concentrations.
The discriminant analysis (PLS-DA) indicated that the
treatment with BaP for 21 days induced specific
metabolomic patterns that enabled class assignment of
the hamsters (PLS-DA, Figure 2d). The PLS-DA score
plot revealed that the control and treatment group were
Table 3 Plasma lipid concentrations in hypercholesterolemic male hamsters receiving BaP treatment for 0, 3, 7, 10, 14,
and 21 days
T0 T3 T7 T10 T14 T21
Plasma lipids
Triglyceride, mmol/L 2.28 ± 0.15 2.34 ± 0.2 2.48 ± 0.38 2.72 ± 0.45 2.85 ± 0.41 2.51 ± 0.14
Total cholesterol, mmol/L 6.13 ± 0.18 5.22 ± 0.15 5.27 ± 0.12 5.32 ± 0.31 5.51 ± 0.22 6.07 ± 0.31
HDL cholesterol, mmol/L 2.69 ± 0.1 3.21 ± 0.17* 3.06 ± 0.12 3.03 ± 0.12 3.11 ± 0.01 3.7 ± 0.13***
Non HDL cholesterol, mmol/L 3.44 ± 0.1 1.94 ± 0.25*** 2.18 ± 0.12*** 2.26 ± 0.2*** 2.39 ± 0.14** 2.37 ± 0.28**
TC/HDL cholesterol Ratio 2.3 ± 0.05 1.64 ± 0.1*** 1.73 ± 0.06*** 1.74 ± 0.05*** 1.76 ± 0.03*** 1.64 ± 0.08***
Notes: Hamsters were fed high fat diet for 4 weeks, followed by high fat and BaP treatment for 0, 3, 7, 10, 14, and 21 days. Values are mean ± SE, N = 10 (T0) or
N = 8 (T3, T7, T10, T14, and T21). * P < 0.05; ** P < 0.01, *** P < 0.001 when compared with T0 group. Statistical analysis ANOVA with Tukey’s procedure was used,
SPSS software.
Table 2 Anthropometrics of hypercholesterolemic male hamsters receiving BaP treatment for 0, 3, 7, 10, 14, and 21 days
T0 T3 T7 T10 T14 T21
Anthropometric data
Body weight gain, g/4 wks 32.7 ± 2.1 40.8 ± 3.7 50.6 ± 6.2* 44.2 ± 3.0 34.4 ± 3.5 39.8 ± 2.9
Food intake, g/d 7.1 ± 0.1 7.4 ± 0.2 7.5 ± .02 7.4 ± 0.2 6.9 ± 0.2 7.4 ± 0.1
Food efficiency ratio, g gain/g feed 0.16 ± 0.01 0.2 ± 0.02 0.22 ± 0.01* 0.2 ± 0.01 0.17 ± 0.01 0.19 ± 0.01
Fluid intake,PAZ/water 1.0 ± 0.0 0.96 ± 0.04 0.95 ± 0.05 1.1 ± 0.04 1.0 ± 0.06 1.1 ± 0.04
Liver *102/body weight 4.6 ± 0.1 4.9 ± 0.1 4.7 ± 0.1 4.8 ± 0.1 4.7 ± 0.1 4.5 ± 0.2
Notes: Hamsters were fed high fat diet for 4 weeks, followed by high fat and BaP treatment for 0, 3, 7, 10, 14, and 21 days. Values are mean ± SE, N = 10 (T0) or
N = 8 (T3, T7, T10, T14, and T21). * P < 0.05 when compared with T0 group. Statistical analysis ANOVA with Tukey’s procedure was used, SPSS software.
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clearly separated by principal component 1. In addition,
the two-dimensional PLS plot (Figure 3a,b) allowed for
the evaluation of BaP treatment on changes in the
plasma metabolome. For instance, the treatment with
BaP for 21 days induced a significant coefficient of
determination R2 = 0.7, when the data were correlated
with the plasma lipid profile (Figure 3a). The PLS regres-
sion between the NMR variables and the plasma lipid
profile revealed that 70% of the variations in the lipid
profile can be predicted by different treatment condi-
tions (water vs. BaP). Furthermore, as determined by the
PLS analysis, HDL-C concentrations were positively cor-
related with the plasma metabolomic profile (R2 = 0.62),
indicating that the composition shift toward the higher
density lipoproteins is reflected in the change in con-
centrations of some of the small metabolites present in
plasma (Figure 3b).
A total of fifty plasma metabolites from the control and
treatment groups were identified and quantified using
Chenomx NMR Suite software, including amino acids
(leucine, isoleucine, valine), organic acids (3-hydroxybu-
tyrate, lactate, acetate, acetoacetate, citrate, pyruvate,
creatine, creatinine), carbohydrates (glucose, galactitol,
glucitol) and phospholipid-associated molecules. The me-
tabolites that had a significantly lower concentration in
the group that received BaP for 21 days are summarized
in Table 4. Results indicated that the concentrations of
choline, phosphocholine, glycerol-phosphocholine, beta-
ine, and carnitine, were significantly lowered in T21 group
as compared with T0. Treatment of hypercholesterolemic
hamsters with BaP also resulted in decreased levels of
several amino acids (arginine, leucine, isoleucine, threo-
nine, taurine), as well as some other important molecules
(3-hydroxy-butyrate, acetate, glycerol) involved in fatty
acid metabolism.
Discussion
In our first study pertaining to PAZ, we determined that
simultaneous administration of PAZ along with a high
fat diet regimen improved the plasma lipid profile, by
increasing the HDL-C concentrations and decreasing the
non-HDL cholesterol, as well as the TC/HDL-C ratio.
Also, the shift in lipoprotein concentration toward the
higher density molecules was observed in the previous
investigation. Moreover, the expression levels of important
genes involved in HDL metabolism/reverse cholesterol
transport were beneficially altered upon administration of
PAZ and its biologically active subfraction [7].
The present study was designed to examine the thera-
peutic effect of BaP in the same diet-induced hypercho-
lesterolemic hamster model used in our previous study
[7]. More specifically, the objective of the current study
was to determine the efficacy of BaP on plasma lipids
and metabolomic profile of animals that had already
attained a hypercholesterolemic state. Also, the aim was
to document the earliest time point at which the plasma
profile was modified after treatment with BaP. As this is
the first study examining the plasma metabolomic pro-
file of hypercholesterolemic hamsters treated with BaP, it
is important to determine the changes in the concentra-
tion of small molecular weight metabolites following
BaP therapy.
Due to interspecies differences in lipoprotein metabo-
lism, it is essential to study metabolic changes in a non-
primate model that develop the most similarities to the
human disease. The hamster model used in our study has
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Figure 1 Relative levels of hepatic mRNA expression of Apo A1 gene in hypercholesterolemic hamsters. Animals were fed a high fat diet
for 4 weeks, followed by high fat diet plus BaP for 0, 3, 7, 10, 14, and 21 days, respectively. Values were calculated as mean of threshold cycle
values; N = 8 animals per group (N = 5 for T0 group). Each mRNA was normalized with GAPDH and is expressed as a fold change. Abbreviations:
Apolipoprotein A1, ApoA1; Biologically active fraction of ProAlgaZyme, BaP; glyceraldehydes-3-phosphate dehydrogenase, GAPDH.
Geamanu et al. Nutrition & Metabolism 2013, 10:55 Page 6 of 10
http://www.nutritionandmetabolism.com/content/10/1/55
been previously found to be appropriate for exploring
hypercholesterolemia associated with dietary changes
[25,26] and the high fat diet used was previously reported
to indeed induce hypercholesterolemia in hamsters [7].
Animals consumed similar amounts of diet and fluid
throughout the study, however the hamsters in group T7
had a significant increase in body weight, as well as in the
food efficiency ratio (g gain/g feed). Since we did not
analyze body composition, we cannot speculate on the
reason for this increase. The results of this therapeutic in-
vestigation reveal an improvement in the plasma lipo-
protein profile upon administration of BaP, showing a
significant reduction in non-HDL cholesterol and the TC/
HDL-C ratio in all treatment groups, as well as a signifi-
cant increase in plasma HDL-C concentration. In
addition, there was a moderate (T7, T10, and T14 groups)
and a highly significant increase (T21 group) in the
hepatic mRNA levels of the Apo A1 gene, which is in-
volved in the production of nascent HDL particles. Ad-
ministration of PAZ and its biologically active fraction
(BaP) showed a significant improvement in the plasma
lipid profile, when fed to hypercholesterolemic hamsters.
In our previous study, when PAZ or BaP were adminis-
tered for 4 weeks as preventative agents, the hepatic
mRNA expression for Apo A1, CETP, ATP-binding cas-
sette transporter, member 1 (ABCA1), and scavenger re-
ceptor class B, member 1 (SRB1) were evaluated. However
as the data only showed strong effects on Apo A1 and
CETP (~ 5-fold increase in Apo A1 and 2-fold decrease in
CETP expression), we focused only on these genes in the
current study. In a trend similar to the earlier study, we
saw an increase in the Apo A1 expression in this study as
well. However, the CETP expression was not significantly
inhibited in the timeframe of this study. Both studies also
Figure 2 Characterization of the plasma metabolomic changes induced by BaP. 2a. CMPG_PCA score plot revealed that T0 and T21 groups
were clearly separated along PC1 and PC2; 2b. CMPG_PCA corresponding loading plot indicating the regions of the spectra that are responsible
for the group separation; 2c. OPLS_S-Plot used to identify possible metabolites that correlate the metabolomic profile to HDL-C concentration;
2d. Two-dimensional PLS-DA score plot showing group discrimination based on treatment received. Notes: T0, high fat diet and water; T21, high
fat diet and BaP for 21 days. N = 8 hamsters per group. Abbreviations: Biologically active fraction of ProAlgaZyme, BaP; Carr-Purcell-Meiboom-Gill,
CPMG; orthogonal projections to latent structures, OPSL; principal component, PC; principal components analysis, PCA; partial least squares-
discriminant analysis, PLS-DA.
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showed a lowering of non-HDL cholesterol. Whether
or not BaP had any effect on cholesterol synthesis via
the enzymatic activity of HMG-Co A reductase was not
the focus of this study and hence not examined. Thus
the mechanism by which non-HDL cholesterol may
have decreased may be speculated, but needs further
exploration.
Further, we analyzed the metabolomic plasma profile
of hypercholesterolemic hamsters treated with BaP, using
1H NMR spectroscopy and multivariate data analysis.
Previous studies have identified metabolomic pertur-
bations associated with abnormal lipoprotein profile,
kidney disease associated with type I diabetes, insulin
resistance, and atherosclerosis using NMR spectroscopy -
the latter has become a widely used method in the last
decade [27,28].
Plasma includes both high molecular weight proteins and
lipoproteins, as well as low molecular weight metabolites.
Hence, the standard plasma one-dimensional 1H NMR
spectrum is dominated by the broad resonance peaks from
the high molecular weight components. The CPMG
echo pulse technique was used to suppress the reson-
ance from the macromolecules and emphasize the low
molecular weight metabolites, thus revealing subtle bio-
chemical information from the plasma samples. A clear
separation of the groups was obtained with the PCA
and PLS-DA score plots, showing changes in plasma
metabolomic profiles due to BaP intervention. PCA
Figure 3 Correlation of the BaP induced plasma metabolomic and lipid profile. Changes among the metabolomic score values ([t1]) of
individual hamsters fed a high fat diet and different drinking fluids (water or BaP) are plotted along with the corresponding individual plasma
lipid profile scores ([u1]), as determined by the PLS analysis. The coefficient of determination (R2) among [t1] and [u1] that was calculated after
linearization of the relationship is indicated. 3a. Relationship between the plasma metabolomic profile and complete lipid profile (R2 = 0.7) 3b.
Relationship between the plasma metabolomic profile and plasma HDL-C (R2 = 0.62). Notes: T0, high fat diet and water; T21, high fat diet and BaP
for 21 days. N = 8 hamsters per group. Abbreviations: Biologically active fraction of ProAlgaZyme, BaP; high density lipoprotein cholesterol, HDL-C;
partial least squares, PLS.
Table 4 List of plasma metabolites quantified to be at lower concentrations after 21 days of treatment
Metabolites Peak regions (ppm) Metabolites Peak regions (ppm)
2-Aminobutyrate 1.0,1.9,3.7 Glucitol 3.6, 3.7, 3.8
3-Hydroxybutyrate 1.2,2.3,2.4,4.1 Glycerol 3.6,3.8
Acetate 1.9 Isoleucine 0.9,1.0,1.2,1.5,2.0,3.7
Arabinitol 3.6,3.7,3.8,3.9 Lactate 1.3,4.1
Arginine 1.6,1.7,1.9,3.2,3.8 Leucine 0.9,1.7,3.7
Betaine 3.3,3.9 Phosphocholine 3.2,3.6,4.1
Carnitine 2.4,3.2,3.4,4.6 Glycero-phosphocholine 3.2,3.6,3.7,3.9,4.3
Choline 3.2,3.5,4.1 Taurine 3.2,3.4
Galactitol 3.7,4.0 Threonine 1.3,3.6,4.3
Notes: Plasma metabolites found to be significantly lower in T21 group as compared with T0 group. The metabolites were quantified using the Chenomx 7.6 NMR
Suite database and significance was obtained using 2 tailed Student t-test, P < 0.05. T0, high fat diet and water; T21, high fat diet and BaP for 21 days, N = 4
hamsters/group for quantification of metabolites.
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loading plots were analyzed to identify the unique
regions in the spectra and hence the metabolites
responsible for the strong separation of the groups. In
addition, the S-Plot generated a set of variables that are
most reliably predictive of the changes in the plasma
HDL-C concentration. Variables that are furthest away
from the origin in the S-Plot are considered as potential
biomarkers. The Chenomx NMR Suite software was
used as the decisive tool in identification and qualifica-
tion of important low molecular weight metabolites.
It is now well established that a high fat diet is highly
correlated with an atherogenic outcome. Independent
from the effect of a high fat diet on lipid profiles, a num-
ber of recent metabolomic studies have identified abnor-
malities in branched chain amino acids [29], choline,
betaine, and trimethylamine N-oxide (TMAO) metabo-
lism as being highly increased in subjects with atheros-
clerosis, heart failure, and other cardiovascular diseases
[30-32]. After screening more than 2000 metabolites from
a large cohort study (n = 1,876), Wang et al. [32] found
that a unique cluster of three phospholipid-associated
molecules, more specifically choline, betaine, and the final
metabolite, TMAO are linked to or predictive of CVD
risk. It has been shown that increased levels of these me-
tabolites promoted up-regulation of several macrophage
scavenger receptors that correlated with atherosclerosis,
making these phospholipid metabolites independent pre-
dictors for the risk of a clinical vascular event. Even
though cholesterol and triglycerides remain key culprits in
atherosclerosis, the new findings have shifted the attention
towards the phosphatidylcholine biosynthesis pathway for
additional information related to risk for CVD. Plasma
levels of choline and betaine are dependent on the
proatherosclerotic phospholipid-rich diet, and are consid-
ered key risk factors, rather than direct markers of CVD
[33]. After quantification of these metabolites in our
plasma samples, we observed that the group which
received the high fat diet and BaP for 21 days had signifi-
cantly lower levels of betaine, choline, phosphocholine,
and glycerol-phosphocholine, as compared with the ani-
mals that received the high fat diet and water.
Another recently studied metabolite that contains a
trimethylamine structure similar to that of choline is L-
carnitine. Its fundamental role is to transport fatty acids
into the mitochondrial compartment [34], and it has
been associated with potential health risk related to
CVD [35]. It has been shown that TMAO, and its pre-
cursors choline and carnitine suppress in vivo reverse
cholesterol transport, and elevated levels of plasma
carnitine in humans are significantly associated with risk
for coronary artery disease, peripheral artery disease,
and overall CVD [36]. Our metabolomics data showed a
significantly lower plasma concentration of carnitine in
the group that received BaP for 21 days, as compared
with the group that received a high fat diet and water.
These findings, in conjunction with the increase in
plasma HDL-C, along with the decrease in non-HDL
cholesterol and the TC/HDL-C ratio, all considered con-
tributory factors towards development of heart disease,
are very exciting. It may be interesting to perform a
follow up metabolomics analysis at the earlier time
points of the study, to determine whether or not the
changes in plasma lipids causes the changes in the meta-
bolite concentrations or vice-versa.
Conclusion
In this study we have demonstrated that the dietary
intervention with BaP can cause a beneficial change in
the lipid and metabolomic profile of diet induced hyper-
cholesterolemia in hamsters. The metabolomic profile of
the hamsters correlated strongly with the plasma lipid
profile and HDL-C concentrations, thereby showing that
BaP intake was beneficial in concomitant improvement
of both the plasma lipid profile and the metabolomic
profile. In addition to improving the established risk fac-
tors associated with CVD, mainly increasing HDL-C,
and up-regulating the mRNA expression of the Apo A1
gene, we identified the potentially valuable effect of the
algal infusion on relatively new predictors of atheroscle-
rosis, namely betaine, carnitine, and choline. This research
illustrates the power of the metabolomics approach to
drive biomarker discovery and generate hypotheses for
new treatments, thereby opening exciting avenues for
future research.
Abbreviations
Apo A1: Apolipoprotein A1; ABCA1: ATP-binding cassette transporter
member 1; BaP: Biologically active fraction of ProAlgaZyme; CETP: Cholesteryl
ester transfer protein; CPMG: Carr-Purcell-Meiboom-Gill; CVD: Cardiovascular
disease; D2O: Deuterium oxide; EDTA: Ethylenediaminetetraacetic acid;
GAPDH: Glyceraldehydes-3-phosphate dehydrogenase; HDL-C: High density
lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol;
NMR: Nuclear magnetic resonance; OPLS: Orthogonal projections to latent
structures; PAZ: ProAlgaZyme; PCA: Principal component analysis; PLS: Partial
least squares; PLS-DA: Partial least squares-discriminant analysis; RT-
PCR: Reverse transcriptase polymerase chain reaction; SRB1: Scavenger
receptor class B member 1; TMAO: Trimethylamine N-oxide; TC: Total
cholesterol; TG: Triglycerides.
Competing interests
AG and SVG have rights to an application covering the biologically activity of
PAZ. NS, PK and AGoja report no conflicts of interest with this work.
Authors’ contributions
AG contributed to the study design, participated in sample collection and
analysis, interpreted the data and drafted the manuscript. AGoja contributed
to NMR data acquisition and multivariate data analysis. NS participated in
sample collection and analysis. PK performed the cardiac puncture
procedure and assisted with the preparation of the manuscript. SG, the PI,
supervised all areas of the research, data analysis and manuscript. All authors
read and approved the final manuscript.
Acknowledgments
ProAlgaZyme infusion was fractionated and provided by Oxford Biomedical
Research (Rochester Hills, MI).
Geamanu et al. Nutrition & Metabolism 2013, 10:55 Page 9 of 10
http://www.nutritionandmetabolism.com/content/10/1/55
Received: 28 June 2013 Accepted: 21 August 2013
Published: 27 August 2013
References
1. Jones ML, Tomaro-Duchesneau C, Martoni CJ, Prakash S: Cholesterol
lowering with bile salt hydrolase-active probiotic bacteria, mechanism of
action, clinical evidence, and future direction for heart health
applications. Expert Opin Biol Ther 2013, 13:631–642.
2. Bocanegra A, Bastida S, Benedi J, Nus M, Sanchez-Montero JM,
Sanchez-Muniz FJ: Effect of seaweed and cholesterol-enriched diets
on postprandial lipoproteinaemia in rats. Br J Nutr 2009,
102:1728–1739.
3. Chen J, Jiang Y, Ma KY, Chen F, Chen ZY: Microalga decreases plasma
cholesterol by down-regulation of intestinal NPC1L1, hepatic LDL
receptor, and HMG-CoA reductase. J Agric Food Chem 2011,
59:6790–6797.
4. Harding SV, Zhao HL, Marinangeli CP, Day AG, Dillon HF, Jain D, Jones PJ:
Red algal cellular biomass lowers circulating cholesterol concentrations
in Syrian golden hamsters consuming hypercholesterolaemic diets.
Br J Nutr 2009, 102:842–847.
5. Misurcova L, Skrovankova S, Samek D, Ambrozova J, Machu L: Health
benefits of algal polysaccharides in human nutrition. Adv Food Nutr Res
2012, 66:75–145.
6. Oben J, Enonchong E, Kuate D, Mbanya D, Thomas TC, Hildreth DJ, Ingolia
TD, Tempesta MS: The effects of ProAlgaZyme novel algae infusion on
metabolic syndrome and markers of cardiovascular health. Lipids Health
Dis 2007, 6:20.
7. Geamanu A, Saadat N, Goja A, Wadehra M, Ji X, Gupta SV: ProAlgaZyme
and its subfractions increase plasma HDL cholesterol via upregulation of
ApoA1, ABCA1, and SBR1, and inhibition of CETP in
hypercholesterolemic hamsters. Nutr Dietary Suppl 2012, 4:17–24.
8. Ramsey SA, Gold ES, Aderem A: A systems biology approach to
understanding atherosclerosis. EMBO Mol Med 2010, 2:79–89.
9. Doring Y, Noels H, Weber C: The use of high-throughput technologies to
investigate vascular inflammation and atherosclerosis. Arterioscler Thromb
Vasc Biol 2012, 32:182–195.
10. Martin JC, Canlet C, Delplanque B, Agnani G, Lairon D, Gottardi G, Bencharif
K, Gripois D, Thaminy A, Paris A: 1H NMR metabonomics can differentiate
the early atherogenic effect of dairy products in hyperlipidemic
hamsters. Atherosclerosis 2009, 206:127–133.
11. Coen M, Holmes E, Lindon JC, Nicholson JK: NMR-based metabolic
profiling and metabonomic approaches to problems in molecular
toxicology. Chem Res Toxicol 2008, 21:9–27.
12. Wei L, Liao P, Wu H, Li X, Pei F, Li W, Wu Y: Metabolic profiling studies on
the toxicological effects of realgar in rats by (1)H NMR spectroscopy.
Toxicol Appl Pharmacol 2009, 234:314–325.
13. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A,
Fearnside J, Tatoud R, Blanc V, Lindon JC, et al: Metabolic profiling
reveals a contribution of gut microbiota to fatty liver phenotype
in insulin-resistant mice. Proc Natl Acad Sci USA 2006,
103:12511–12516.
14. Walsh MC, Brennan L, Malthouse JP, Roche HM, Gibney MJ: Effect of
acute dietary standardization on the urinary, plasma, and salivary
metabolomic profiles of healthy humans. Am J Clin Nutr 2006,
84:531–539.
15. Bertram HC, Hoppe C, Petersen BO, Duus JO, Molgaard C, Michaelsen
KF: An NMR-based metabonomic investigation on effects of milk and
meat protein diets given to 8-year-old boys. Br J Nutr 2007,
97:758–763.
16. Jove M, Ayala V, Ramirez-Nunez O, Serrano JC, Cassanye A, Arola L, Caimari
A, Del Bas JM, Crescenti A, Pamplona R, Portero-Otin M: Lipidomic and
metabolomic analyses reveal potential plasma biomarkers of early
atheromatous plaque formation in hamsters. Cardiovasc Res 2013,
97:642–652.
17. Williams RE, Lenz EM, Lowden JS, Rantalainen M, Wilson ID: The
metabonomics of aging and development in the rat: an investigation
into the effect of age on the profile of endogenous metabolites in the
urine of male rats using 1H NMR and HPLC-TOF MS. Mol Biosyst 2005,
1:166–175.
18. Dorfman SE, Wang S, Vega-Lopez S, Jauhiainen M, Lichtenstein AH:
Dietary fatty acids and cholesterol differentially modulate HDL
cholesterol metabolism in Golden-Syrian hamsters. J Nutr 2005,
135:492–498.
19. Yang H, Pang W, Lu H, Cheng D, Yan X, Cheng Y, Jiang Y:
Comparison of metabolic profiling of cyanidin-3-O-galactoside and
extracts from blueberry in aged mice. J Agric Food Chem 2011,
59:2069–2076.
20. Fardet A, Canlet C, Gottardi G, Lyan B, Llorach R, Remesy C, Mazur A, Paris A,
Scalbert A: Whole-grain and refined wheat flours show distinct metabolic
profiles in rats as assessed by a 1H NMR-based metabonomic approach.
J Nutr 2007, 137:923–929.
21. Eriksson L, Andersson PL, Johansson E, Tysklind M: Megavariate analysis of
environmental QSAR data. Part II–investigating very complex problem
formulations using hierarchical, non-linear and batch-wise extensions of
PCA and PLS. Mol Divers 2006, 10:187–205.
22. Pears MR, Cooper JD, Mitchison HM, Mortishire-Smith RJ, Pearce DA, Griffin
JL: High resolution 1H NMR-based metabolomics indicates a
neurotransmitter cycling deficit in cerebral tissue from a mouse model
of Batten disease. J Biol Chem 2005, 280:42508–42514.
23. Qiao-feng W, Ling-ling G, Shu-guang Y, Qi Z, Sheng-feng L, Fang Z,
Hai-yan Y, Yong T, Xian-zhong Y: A(1)H NMR-based metabonomic study
on the SAMP8 and SAMR1 mice and the effect of electro-acupuncture.
Exp Gerontol 2011, 46:787–793.
24. Weljie AM, Newton J, Mercier P, Carlson E, Slupsky CM: Targeted profiling:
quantitative analysis of 1H NMR metabolomics data. Anal Chem 2006,
78:4430–4442.
25. Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the
metabolic syndrome. Am J Cardiol 1998, 81:18B–25B.
26. Castelli WP, Anderson K, Wilson PW, Levy D: Lipids and risk of
coronary heart disease. The Framingham study. Ann Epidemiol 1992,
2:23–28.
27. Hanukoglu I: Steroidogenic enzymes: structure, function, and role in
regulation of steroid hormone biosynthesis. J Steroid Biochem Mol Biol
1992, 43:779–804.
28. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman
AH, Posma JL, van Tol A, Kastelein JJ: Efficacy and safety of a novel
cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a
randomized phase II dose–response study. Circulation 2002,
105:2159–2165.
29. Jones RD, Repa JJ, Russell DW, Dietschy JM, Turley SD: Delineation of
biochemical, molecular, and physiological changes accompanying
bile acid pool size restoration in Cyp7a1(−/−) mice fed low levels
of cholic acid. Am J Physiol Gastrointestin Liver Physiol 2012,
303:G263–G274.
30. Kang SM, Park JC, Shin MJ, Lee H, Oh J, Ryu do H, Hwang GS, Chung
JH: (1)H nuclear magnetic resonance based metabolic urinary
profiling of patients with ischemic heart failure. Clin Biochem 2011,
44:293–299.
31. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ: Effect of statins on
HDL-C: a complex process unrelated to changes in LDL-C: analysis of the
VOYAGER Database. J Lipid Res 2010, 51:1546–1553.
32. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B,
Feldstein AE, Britt EB, Fu X, Chung YM, et al: Gut flora metabolism of
phosphatidylcholine promotes cardiovascular disease. Nature 2011,
472:57–63.
33. Heather LC, Wang X, West JA, Griffin JL: A practical guide to metabolomic
profiling as a discovery tool for human heart disease. J Mol Cell Cardiol
2013, 55:2–11.
34. Bremer J: Carnitine–metabolism and functions. Physiol Rev 1983,
63:1420–1480.
35. Rebouche CJ, Seim H: Carnitine metabolism and its regulation in
microorganisms and mammals. Annu Rev Nutr 1998, 18:39–61.
36. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu
Y, Li L, et al: Intestinal microbiota metabolism of l-carnitine, a nutrient in
red meat, promotes atherosclerosis. Nat Med 2013, 19:576–585.
doi:10.1186/1743-7075-10-55
Cite this article as: Geamanu et al.: ProAlgaZyme subfraction improves
the lipoprotein profile of hypercholesterolemic hamsters, while
inhibiting production of betaine, carnitine, and choline metabolites.
Nutrition & Metabolism 2013 10:55.
Geamanu et al. Nutrition & Metabolism 2013, 10:55 Page 10 of 10
http://www.nutritionandmetabolism.com/content/10/1/55
